Characteristics associated with synthetic cannabinoid use among patients treated in a public psychiatric emergency setting

References

• Castaneto M, Gorelick D, Desrosiers N, Hartman R, Pirard S, Huestis M. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014;144:12–41.
   PubMed Web of Science ®Google Scholar
• Egan K, Suerken C, Reboussin B, Spangler J, Wagoner K, Sutfin E, Debinski B, Wolfson M. K2 and Spice use among a cohort of college students in southeast of the USA. Am J Drug Alchohol Abuse 2015;41:317–322.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Acosta P. Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug Alcohol Depend 2015;149:194–202.
   PubMed Web of Science ®Google Scholar
• Van Hout M, Brennan R. Heads held high: an exploratory study of legal highs in pre-legislation Ireland. J Ethn Substan Abuse 2012;10:256–272.
   Google Scholar
• Law R, Schier M, Martin C, Chang A, Wolkin A. Notes from the field: Increase in reported adverse health effects related to synthetic cannabiniod use – United State, January-May 2015. Morbidity Mortatly Week Rep CDC 2015;64:618–619.
   PubMed Web of Science ®Google Scholar
• Trecki J, Gerona R, Schwartz M. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 2015;373:103–105.
   PubMed Web of Science ®Google Scholar
• Forrester M, Haywood T. Geographic distribution of synthetic cannabinoid exposures reported to texas poison centers. Am J Drug Alcohol Abuse 2012;38:603–608.
   PubMed Web of Science ®Google Scholar
• Kronstrand R, Roman M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 2013;37:534–541.
   PubMed Web of Science ®Google Scholar
• Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, et al. “Spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol 2013;28:379–389.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012;21:320–326.
   PubMed Web of Science ®Google Scholar
• Zawilska J, Wojcieszak J. Spice/K2 drugs–more than innocent substitutes for marijuana. Int. J. Neuropsychopharmacol 2014;17:509–525.
   PubMed Web of Science ®Google Scholar
• Van Der Veer N, Friday J. Persistent psychosis following the use of Spice. Schizophrenia Res 2011;130:285–286.
   PubMed Web of Science ®Google Scholar
• Berry-Caban C, Ee J, Ingram V, Berry C, Kim E. Synthetic cannabinoid overdose in a 20-year-old male US soldier. Subst Abus 2013;34:70–72.
   PubMed Web of Science ®Google Scholar
• Durand D, Delgado L, Parra-Pellot D, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses 2015;8:205–208.
   PubMedGoogle Scholar
• Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: A case series. Am J Psychiatry 2011;168:1119.
   PubMed Web of Science ®Google Scholar
• Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the US military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the US Armed Forces. Mil Med 2012;177:1041–1048.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Dunn K, Fry J, Girling E. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 2012;120:238–241.
   PubMed Web of Science ®Google Scholar
• Winstock A, Barratt M. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131:106–111.
   PubMed Web of Science ®Google Scholar
• Kelly BC, Wells BE, Pawson M, Leclair A, Parsons JT, Golub SA. Novel psychoactive drug use among younger adults involved in US nightlife scenes. Drug Alcohol Rev 2013;32:588–593.
   PubMed Web of Science ®Google Scholar
• Hoyte C, Jacob J, Monte A, Al-Jumaan M, Bronstein A, Heard K. A Characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med 2012;60:435–438.
   PubMed Web of Science ®Google Scholar
• Springer Y, Shafer A, Gerona R. Increase in hospital emergency department visits related to use of synthetic cannabiniods – municipality of anchorage, July to September. State Alaska Epidemiol Recommendations Rep 2015;17:1–8.
   Google Scholar
• Palamar JJ, Su MK, Hoffman RS. Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011–2014. Am J Drug Alcohol Abuse 2016;42:39–47.
   PubMed Web of Science ®Google Scholar
• Kunins H. Increase in synthetic cannabinoid (K2)-related adverse events and emergency department visits, New York City. New York City Dep Health Ment Hyg Health Advisory 2015;36:1–2.
   Google Scholar
• Kunins H. Increase in synthetic cannabinoid (K2)-related adverse events and emergency department visits. New York City Department Health Ment Hygi 2016:6:1–2.
   Google Scholar
• Palamar JJ, Barratt MJ. Synthetic cannabinoids: undesirable alternatives to natural marijuana. Am J Drug Alcohol Abuse 2016;42:1–3.
   PubMed Web of Science ®Google Scholar
• Krameddine Y, Silverstone P. How to improve interactions between police and the mentally Ill. Front Psychiatry 2014;5:186.
   PubMed Web of Science ®Google Scholar
• Shapiro G, Cusi A, Kirst M, O’Campo P, Nakhost A, Stergiopoulos V. Co-responding police-mental health programs: A review. Admin Policy Ment Health Ment Health Serv Res 2015;42:606–620.
   PubMed Web of Science ®Google Scholar
• Edwards E, Bunting W, Garcia. The War on Marijuana in Black and White. The American Civil Liberties Union. 2013.
   Google Scholar